Literature DB >> 24080682

Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.

Nathan D Pfeifer1, Arlene S Bridges, Brian C Ferslew, Rhiannon N Hardwick, Kim L R Brouwer.   

Abstract

Basolateral efflux clearance (CLBL) contributes significantly to rosuvastatin (RSV) elimination in sandwich-cultured hepatocytes (SCH). The contribution of CLBL to RSV hepatic elimination was determined in single-pass isolated perfused livers (IPLs) from wild-type (WT) and multidrug resistance-associated protein 2 (Mrp2)-deficient (TR(-)) rats in the absence and presence of the P-glycoprotein and breast cancer resistance protein (Bcrp) inhibitor, elacridar (GF120918); clearance values were compared with SCH. RSV biliary clearance (CLBile) was ablated almost completely by GF120918 in TR(-) IPLs, confirming that Mrp2 and Bcrp primarily are responsible for RSV CLBile. RSV appearance in outflow perfusate was attributed primarily to CLBL, which was impaired in TR(-) IPLs. CLBL was ≈ 6-fold greater than CLBile in the linear range in WT IPLs in the absence of GF120918. Recovery of unchanged RSV in liver tissue increased in TR(-) compared with WT (≈ 25 versus 6% of the administered dose) due to impaired CLBL and CLBile. RSV pentanoic acid, identified by high-resolution liquid chromatography-tandem mass spectroscopy, comprised ≈ 40% of total liver content and ≈ 16% of the administered dose in TR(-) livers at the end of perfusion, compared with ≈ 30 and 3% in WT livers, consistent with impaired RSV excretion and "shunting" to the metabolic pathway. In vitro-ex vivo extrapolation between WT SCH and IPLs (without GF120918) revealed that uptake clearance and CLBL were 4.2- and 6.4-fold lower, respectively, in rat SCH compared with IPLs; CLBile translated almost directly (1.1-fold). The present IPL data confirmed the significant role of CLBL in RSV hepatic elimination, and demonstrated that both CLBL and CLBile influence RSV hepatic and systemic exposure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24080682      PMCID: PMC3836312          DOI: 10.1124/jpet.113.208314

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  60 in total

1.  ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.

Authors:  Liyue Huang; Yi Wang; Scott Grimm
Journal:  Drug Metab Dispos       Date:  2006-01-13       Impact factor: 3.922

2.  Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.

Authors:  Wei Zhang; Bang-Ning Yu; Yi-Jing He; Lan Fan; Qing Li; Zhao-Qian Liu; An Wang; Ya-Li Liu; Zhi-Rong Tan; Yuan-Fei Huang; Hong-Hao Zhou
Journal:  Clin Chim Acta       Date:  2006-05-13       Impact factor: 3.786

3.  Variability in human hepatic MRP4 expression: influence of cholestasis and genotype.

Authors:  U Gradhand; T Lang; E Schaeffeler; H Glaeser; H Tegude; K Klein; P Fritz; G Jedlitschky; H K Kroemer; I Bachmakov; B Anwald; R Kerb; U M Zanger; M Eichelbaum; M Schwab; M F Fromm
Journal:  Pharmacogenomics J       Date:  2007-04-03       Impact factor: 3.550

4.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

Authors:  Richard H Ho; Rommel G Tirona; Brenda F Leake; Hartmut Glaeser; Wooin Lee; Christopher J Lemke; Yi Wang; Richard B Kim
Journal:  Gastroenterology       Date:  2006-03-06       Impact factor: 22.682

5.  ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4).

Authors:  Maria Rius; Johanna Hummel-Eisenbeiss; Dietrich Keppler
Journal:  J Pharmacol Exp Ther       Date:  2007-10-24       Impact factor: 4.030

6.  Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.

Authors:  Paul D Martin; Mike J Warwick; Aaron L Dane; Charlie Brindley; Tracy Short
Journal:  Clin Ther       Date:  2003-10       Impact factor: 3.393

7.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.

Authors:  Dennis W Schneck; Bruce K Birmingham; Julie A Zalikowski; Patrick D Mitchell; Yi Wang; Paul D Martin; Kenneth C Lasseter; Colin D A Brown; Amy S Windass; Ali Raza
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

Review 8.  Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.

Authors:  L Z Benet; C L Cummins; C Y Wu
Journal:  Int J Pharm       Date:  2004-06-11       Impact factor: 5.875

9.  Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.

Authors:  Paul D Martin; Mike J Warwick; Aaron L Dane; Steve J Hill; Petrina B Giles; Paul J Phillips; Eva Lenz
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

10.  Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport.

Authors:  Chitrawina Mahagita; Steven M Grassl; Pawinee Piyachaturawat; Nazzareno Ballatori
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-04-05       Impact factor: 4.052

View more
  7 in total

1.  Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Authors:  James J Beaudoin; Jacqueline Bezençon; Yanguang Cao; Katsuhiko Mizuno; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2018-11-30       Impact factor: 3.922

2.  Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Authors:  B C Ferslew; C K Johnston; E Tsakalozou; A S Bridges; M F Paine; W Jia; P W Stewart; A S Barritt; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2015-03-15       Impact factor: 6.875

3.  Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.

Authors:  Brian C Ferslew; Kathleen Köck; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2014-06-23       Impact factor: 3.922

4.  Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substrates.

Authors:  Brian C Ferslew; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2014-02-22       Impact factor: 4.849

5.  Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease.

Authors:  Jacqueline Bezençon; James J Beaudoin; Katsuaki Ito; Dong Fu; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-06-03       Impact factor: 3.922

Review 6.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

7.  A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions.

Authors:  R Li; H A Barton; T S Maurer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.